This article provides a detailed analysis of Granules India Ltd Share Price Target from 2025 to 2030. It covers current share performance, historical price trends, financial growth, and long-term potential. In this article, we also discuss key investors, shareholding pattern, market position, and expert forecasts.
Overview of Granules India Ltd
What is Granules India Limited?
Granules India Limited is a prominent Indian pharmaceutical manufacturing company, founded in 1984 and headquartered in India. The company specializes in the production and sale of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages. With a strong focus on cost-effective, high-quality products, Granules India operates globally and serves a wide range of customers including major pharmaceutical giants.
Key Features of Granules India Limited
- Core Business: Focused on the manufacturing and distribution of APIs, PFIs, and Finished Dosages across therapeutic categories like pain management, anti-infectives, and cardiovascular drugs.
- Operational Scale: Maintains a vertically integrated business model, enhancing cost efficiency and quality control across the pharmaceutical value chain.
- Global Presence: Supplies products to over 60 countries, with strong partnerships and exports to regulated markets like the US, Europe, and Japan.
- Strategic Subsidiaries: Includes Granules Pharmaceuticals, Inc., which focuses on the US market and reinforces the company’s international expansion.
- Workforce: Employs approximately 4,066 professionals as of 2025, with a robust presence in R&D, manufacturing, and regulatory compliance.
- Manufacturing Facilities: Operates multiple US FDA and EU GMP-approved facilities in India and abroad, supporting its global regulatory compliance.
- Innovation & Growth: Investing in high-value APIs, new product development, and expanding capacities to meet global demand efficiently.
Information about Granules India Limited
| Information | Details |
|---|---|
| Website | granulesindia.com |
| Headquarters | India |
| Founded | 1984 |
| Founder | Krishna Prasad Chigurupati |
| CEO | Dr. K.V.S. Ram Rao |
| Stock Exchange Listings | BSE: 532482, NSE: GRANULES |
| Employees | 4,066 (as of 2025) |
| Share Price (as of Jul 18, 2025) | ₹496 (-1.25%) |
| Key Business | Manufacturing and selling of APIs, PFIs, and Finished Dosages |
| Key Subsidiaries | Granules Pharmaceuticals, Inc. |
| Global Operations | Supplies to over 60 countries including regulated markets like US and EU |
| Manufacturing Facilities | Multiple US FDA and EU GMP-certified plants across India |
Overview of Granules India Ltd. Share Price Today
Granules India Ltd. Share Price Fundamental Data
| Fundamental Metric | Value |
|---|---|
| Market Cap | ₹12,039 Cr. |
| Current Price | ₹496 |
| 52-Week High / Low | ₹725 / ₹412 |
| Stock P/E | 25.1 |
| Book Value | ₹153 |
| Dividend Yield | 0.30% |
| ROCE | 15.1% |
| ROE | 13.8% |
| Face Value | ₹1.00 |
Market Position of Granules India Share as of July 2025
As of July 2025, Granules India shows mixed performance. The share fell -1.26% in a day but gained 5.79% in a week and 0.25% over a month. It rose 6.13% in 3 months, while long-term returns remain strong with +60.83% in 3 years and +87.9% in 5 years, despite a -4.4% dip in 1 year.
| Time Period | Returns |
|---|---|
| 1 Day | -1.26% |
| 1 Week | +5.79% |
| 1 Month | +0.25% |
| 3 Months | +6.13% |
| 1 Year | -4.4% |
| 3 Years | +60.83% |
| 5 Years | +87.9% |
Granules India Ltd Share Price Target (2025–2030)
Granules India Ltd Share Price Target for 2025
In 2025, Granules India’s share price is projected to trade between ₹520 – ₹580, supported by stable short-term growth, strong exports, and consistent demand for APIs and formulations.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 520 | 580 |
Granules India Ltd Share Price Target for 2026
By 2026, the share may move between ₹580 – ₹670, driven by higher operational efficiencies, global market expansion, and growth in finished dosages.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2026 | 580 | 670 |
Granules India Ltd Share Price Target for 2027
In 2027, Granules India is expected to trade between ₹650 – ₹770, supported by capacity expansion, regulatory approvals, and steady revenue growth.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2027 | 650 | 770 |
Granules India Ltd Share Price Target for 2028
For 2028, the share may rise to ₹720 – ₹900, with continued R&D investment, product pipeline enhancement, and stronger presence in regulated markets.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2028 | 720 | 900 |
Granules India Ltd Share Price Target for 2029
By 2029, the stock could reach ₹800 – ₹1,050, backed by diversification in therapeutic areas and growing demand in international markets.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2029 | 800 | 1,050 |
Granules India Ltd Share Price Target for 2030
In 2030, Granules India’s share is forecasted to range between ₹900 – ₹1,200, positioning the company as a globally competitive mid-cap pharma player with a balanced portfolio and efficient cost structure.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2030 | 900 | 1,200 |
Granules India Ltd Share Price Target for Tomorrow
Granules India Share Ltd Price History (2003–2025)
| Year | Closing Price (₹) | YoY Change (%) |
|---|---|---|
| 2025 | ₹496.15 | -16.2% |
| 2024 | ₹592.29 | +46.5% |
| 2023 | ₹404.37 | +27.8% |
| 2022 | ₹316.45 | -4.9% |
| 2021 | ₹332.64 | -4.1% |
| 2020 | ₹346.95 | +187.4% |
| 2019 | ₹120.71 | +38.6% |
| 2018 | ₹87.11 | -34.0% |
| 2017 | ₹131.91 | +28.5% |
| 2016 | ₹102.69 | -27.0% |
| 2015 | ₹140.58 | +81.2% |
| 2014 | ₹77.58 | +327.7% |
| 2013 | ₹18.14 | +25.4% |
| 2012 | ₹14.46 | +162.9% |
| 2011 | ₹5.50 | -34.2% |
| 2010 | ₹8.36 | +6.4% |
| 2009 | ₹7.86 | +138.9% |
| 2008 | ₹3.29 | -66.5% |
| 2007 | ₹9.81 | +34.8% |
| 2006 | ₹7.28 | -18.6% |
| 2005 | ₹8.94 | -21.8% |
| 2004 | ₹11.43 | +11.3% |
| 2003 | ₹10.27 | — |
Granules India Ltd Financial Performance (FY 2023 – FY 2025)
| Annual | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total Revenue (₹ Cr.) | 4,494.53 | 4,510.77 | 4,525.70 |
| Revenue Growth (%) | -0.36 | -0.33 | 19.65 |
| Total Expenses (₹ Cr.) | 3,865.11 | 3,963.54 | 3,838.52 |
| Expense Growth (%) | -2.48 | 3.26 | 19.04 |
| PAT (₹ Cr.) | 501.52 | 405.31 | 516.60 |
| PAT Growth (%) | 23.74 | -21.54 | 25.16 |
| Operating Margin (%) | 16.34 | 14.49 | 16.46 |
| Net Profit Margin (%) | 11.19 | 8.99 | 11.44 |
| Basic EPS (₹) | 20.69 | 16.73 | 21.05 |
How to Buy Granules India Ltd Shares
- Choose a Broker
Select a trusted stockbroker that lists Granules India Ltd (NSE: GRANULES, BSE: 532482). Some popular options include:- Zerodha
- Groww
- Upstox
- Angel One
- ICICI Direct
- Open a Trading & Demat Account
Register for a trading and Demat account with your chosen platform. Recommended trading apps:- Zerodha’s Kite
- Groww
- Upstox Pro
- Complete KYC Verification
Upload required documents for identity and address verification, such as:- PAN card
- Aadhaar card / Passport
- Bank account proof
- Add Funds to Your Account
Deposit funds using:- UPI
- Net banking
- Debit card
- IMPS/NEFT
- Search for Granules India Ltd Shares
Look up the company using these stock codes:- NSE: GRANULES
- BSE: 532482
- Place Your Order
Choose the type of order:- Market Order: Buys at the current price instantly.
- Limit Order: Executes only when the share hits your specified price.
- Confirm & Execute
Review the share quantity and order type, then confirm the transaction to complete the purchase. - Monitor Your Investment
Track Granules India Ltd’s performance via your broker’s app or platforms like:- Moneycontrol
- NSE India
- TradingView
Shareholding Pattern of Granules India Ltd as on June 2025 (with Number of Shares)
Promoters:
- Number of Shares: 9,42,03,525
- Percentage: 38.82%
- % Change QoQ: -0.02%
- No. of Shareholders: Data Not Disclosed
FII (Foreign Institutional Investors):
- Number of Shares: 3,21,20,454
- Percentage: 13.24%
- % Change QoQ: -1.90%
DII (Domestic Institutional Investors):
- Number of Shares: 5,70,83,464
- Percentage: 23.52%
- % Change QoQ: +1.06%
Mutual Funds (within DII):
- Number of Shares: 2,96,96,802
- Percentage: 12.24%
- % Change QoQ: +0.66%
Public (Retail & Others):
- Number of Shares: 5,92,36,273
- Percentage: 24.42%
- % Change QoQ: +0.85%
Peer Competitors of Granules India Ltd in the Pharmaceuticals Sector
| Name | Share Price (₹) | Market Cap (₹ Cr) |
|---|---|---|
| Sun Pharma | 1,693.60 | 4,06,351.37 |
| Divi’s Laboratories | 6,731.50 | 1,78,700.17 |
| Cipla | 1,482.30 | 1,19,732.96 |
| Torrent Pharma | 3,521.40 | 1,19,174.82 |
| Mankind Pharma | 2,652.30 | 1,09,468.05 |
| Dr Reddy’s Labs | 1,257.50 | 1,04,948.66 |
| Zydus Lifesciences | 974.95 | 98,102.78 |
| Granules India | 496.15 | 12,038.77 |
Challenges and Risks of Investing in Granules India Ltd
Operational and Market Risks:
- Heavy dependence on U.S. and European markets exposes it to regulatory and pricing pressures.
- Intense competition from domestic and global pharma players in generics and APIs.
- Any delay in FDA/EMA approvals can significantly impact exports and margins.
- Revenue concentration in select drugs/formulations increases business risk.
- Fluctuations in raw material prices (especially Chinese imports) can hurt margins.
Financial and Execution Risks:
- Moderate margins compared to large-cap peers limit profitability upside.
- Capex for expansion and R&D may put pressure on near-term free cash flow.
- Currency volatility can affect export revenue and profit visibility.
- Working capital requirements remain high in pharma supply chains.
- Any regulatory non-compliance may lead to plant shutdowns or product recalls.
Granules India Share Price: Key Growth Drivers
Business Strength & Market Positioning:
- Strong footprint in APIs, PFIs, and finished dosages across global markets.
- Supplies to top global pharmaceutical companies; long-term contracts in place.
- Operational efficiency driven by vertically integrated manufacturing.
- Diversified presence across paracetamol, metformin, ibuprofen, and other key drugs.
- Increasing R&D investments for complex generics and CRAMS.
Financial & Expansion Potential:
- FY24 revenue of ₹4,451 Cr with healthy 10%+ EBITDA margin.
- Net profit of ₹471 Cr and EPS of ₹18.39 indicate strong fundamentals.
- Return ratios like ROCE at 17.4% and ROE at 16.5% show consistent performance.
- Expansion into regulated markets and specialty APIs opens new growth avenues.
- Attracts growing interest from FIIs and mutual funds seeking mid-cap pharma exposure.
Granules India Ltd – FAQs (People Also Ask)
Is Granules India a good stock to buy?
Granules India is considered a fundamentally strong mid-cap pharma stock with consistent revenue growth, export exposure, and a strong API and formulation business. It is often recommended for long-term investors seeking stable growth in the pharmaceutical sector.
What is the share price of Granules India Limited?
As of July 2025, the share price of Granules India Ltd is approximately ₹400 (NSE: GRANULES, BSE: 532482). Prices may vary daily based on market conditions.
What does Granules India Ltd. do?
Granules India is a pharmaceutical manufacturing company engaged in producing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Its key products include Paracetamol, Ibuprofen, and Metformin.
Is Granules a good company?
Yes, Granules India is a reputable company in the Indian pharmaceutical space, with a global presence in over 60 countries, FDA-approved facilities, and consistent performance in both API and formulation exports.
Why is Granules share falling?
Granules India’s share may fall due to temporary factors such as:
- Pressure on margins from raw material costs
- Regulatory concerns or inspection warnings
- Profit booking after rallies
- Broader market sentiment shifts
Is Granules India a multibagger?
Granules India has delivered multibagger returns in the past 10 years. While future performance depends on earnings and global demand, analysts still consider it a promising long-term bet in the pharma sector.
Which share is falling most?
This changes frequently. To know the current most falling stock, check live data on NSE/BSE platforms or financial sites like Moneycontrol or TradingView.
Is Granules India overvalued or undervalued?
As of July 2025, Granules India is considered fairly valued by many analysts, trading at a reasonable P/E compared to industry peers. However, valuations may vary based on future earnings and market sentiment.
Is Granules India debt free?
No, Granules India is not completely debt-free but has significantly reduced its debt in recent years, maintaining a healthy debt-to-equity ratio below 0.5, which reflects prudent financial management.
Who is the owner of Granules?
The company was founded by Mr. Krishna Prasad Chigurupati, who remains a key promoter and chairman of Granules India Ltd.
What is PFI in pharma?
PFI stands for Pharmaceutical Formulation Intermediates – a blend of APIs and excipients used to manufacture final drug dosages, simplifying the formulation process for pharma companies.
Which is best, API or formulation?
Both segments have their advantages:
- API: Higher volume, B2B model, cost-sensitive
- Formulation: Higher margins, brand building, regulated market access
Granules India operates in both, giving it a balanced revenue model.
What is PFI trading?
PFI trading involves the sale and distribution of pre-mixed pharmaceutical formulation intermediates to domestic and international pharma companies for final drug manufacturing.
What is PFI in cars?
In the automobile industry, PFI stands for Port Fuel Injection, a fuel delivery system where fuel is injected into the intake ports of an engine rather than directly into the combustion chamber.